Health Care

Insider sale of 185,000 Precigen shares by Jeffrey Kindler signals a routine RSU divestiture, not a loss of confidence—watch liquidity moves and future milestones.

Inside Monopar’s insider trades: Kim R bought shares at $30 & $14—deep discounts to today’s $113.94—then sold at $110‑$113.84, locking profits as the stock climbs. Insight into potential undervaluation and risk‑managed strategy.

Monopar’s insider buys and sells reveal a balanced strategy—buy low, sell high—underscoring confidence in its cancer pipeline and a measured outlook.

Insider buy by Langer Dennis shows confidence in Quoin’s rare‑disease pipeline, yet the biotech’s low valuation and volatile market caution investors to watch upcoming milestones.

Explore how Fulgent Genetics’ CFO’s sell‑to‑cover trades reveal routine tax‑covering moves, not bad news, and what that means for investors.

Insider confidence at NeuroOne spurs hope: execs buy 110k shares on a low‑price day, backing next‑gen StereoCED and potential human trials.

Insider RSU buy by Sarraf Pasha at CUE Biopharma signals management confidence ahead of key clinical data – a bullish move for investors.

NeuroOne insiders buy 35,000 options, boosting confidence in the company’s StereoCED platform and hinting at potential upside for investors.

Gifford David R’s August 25 sell of 1,779 NHCC shares reveals a tactical divestment, not a bearish bet, amid growing insider buying and a strong earnings beat.

Relay Therapeutics insider selling continues: CEO and execs sell shares at $20, reflecting liquidity moves amid a 412% stock rise.